Patient Perspectives

Real Patients. Real Harm. No Accountability.

Behind every statistic is a patient whose life was changed by a lack of transparency and oversight around mass-compounded GLP-1s.

84%

Americans say FDA approval matters.

But more than half of GLP-1 users mistakenly believe compounded GLP-1s are FDA approved.

2.35x

Higher odds of hospitalization.

Per FDA adverse event data, hospitalization was more common among patients on compounded GLP-1s than those on FDA-approved versions.

Over 80%

Unauthorized shipments entered the U.S.

Nearly 80% of flagged semaglutide shipments and 90% of tirzepatide shipments from unregistered foreign manufacturers made it into the U.S. — a violation of federal law.

These are the stories mass compounders hoped patients would not see.

Kentucky

Acute liver failure and an emergency transplant

A woman from Kentucky was prescribed compounded tirzepatide mixed with Vitamin B12 by her doctor. Within weeks of taking it, she was in acute liver failure. Doctors told her the only chance of survival was an emergency transplant. The API had been sourced from China — from a facility never registered with or inspected by the FDA.

Tennessee

Hospitalized after nearly nine times the standard starting dose

Within 24 hours of her first compounded GLP-1 dose — nearly nine times the standard starting amount — a woman from Tennessee was hospitalized. Weeks later, she was still managing residual side effects. The company’s response: sign away your right to sue.

North Carolina

A refill arrived at triple the concentration

A North Carolina woman’s compounded GLP-1 refill was three times stronger than her last dose — more concentrated, no warning, no explanation. She injected less than the label told her to and still spent days vomiting every 20 minutes. She ended up hospitalized, over $9,000 in debt. The company never responded.

Illinois

Four hospitalizations following his first injection

Within 90 minutes of his first compounded GLP-1 injection, a Chicago man was in the emergency room. Doctors told him, “If you wouldn’t have come in when you did, you would have probably died.” Illinois health authorities are still investigating.

Patients deserve to know what they are taking and who answers when something goes wrong.

These stories are not isolated incidents. They are the predictable result of a system without transparency, consistency, and accountability.